Amgen: Repatha to Be Available Only at Lower List Price Next Year
October 24 2019 - 09:53AM
Dow Jones News
By Colin Kellaher
Amgen Inc. (AMGN) Thursday said Repatha will only be available
at its lower list price next year as the company works to make the
cholesterol drug more affordable.
Amgen last year cut the list price of Repatha by 60% to $5,850 a
year in a bid to reduce out-of-pocket costs, especially for
Medicare patients.
The Thousand Oaks, Calif., biotechnology company also continued
to offer the original list price option of more than $14,000 to
minimize disruption in the supply chain and allow time for payers
and pharmacy benefit managers to modify existing contracts.
Amgen, which reported $91 million in U.S. Repatha sales for the
second quarter, said it will discontinue the Repatha original list
price option Dec. 31.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 24, 2019 09:38 ET (13:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2023 to Mar 2024